Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 7:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Control regimen Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Continuous Adductor Canal Blocks Vs. Low Dose Femoral Nerve Blocks For Early Rehabilitation After Total Knee Arthroplasty

NCT02453321
View directory record Official record
Conditions
Pain, Postoperative, Total Knee Arthroplasty (TKA)
Interventions
Continuous Femoral Nerve Block, Nerve Block, Continuous Adductor Canal, Continuous Sciatic Nerve Block, Bupivacaine
Procedure · Drug
Lead sponsor
Kevin King, DO
Other
Eligibility
18 Years to 75 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 26, 2018 · Synced Sep 10, 2026, 7:48 AM EDT
Terminated Phase 2 Interventional

The PUMA Trial is a Trial of a Single ProHema Modulated-Cord Blood (CB) Unit as Part of a Double CB Transplant in Patients With Hematologic Malignancies.

NCT01627314
View directory record Official record
Conditions
Hematologic Malignancies
Interventions
ProHema-CB, Untreated CB
Biological
Lead sponsor
Fate Therapeutics
Industry
Eligibility
15 Years to 65 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
11
States / cities
Duarte, California • Atlanta, Georgia • Maywood, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2021 · Synced Sep 10, 2026, 7:48 AM EDT
Completed Phase 3 Interventional Results available

A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3)

NCT01646177
View directory record Official record
Conditions
Psoriasis
Interventions
Placebo, 50 mg etanercept, 80 mg ixekizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
41
States / cities
Anaheim, California • Bakersfield, California • Bell Gardens, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Sep 10, 2026, 7:48 AM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC

NCT05611671
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Colitis, Ulcerative
Interventions
MORF-057, Placebo
Drug
Lead sponsor
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
Industry
Eligibility
18 Years to 85 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
8
States / cities
Sun City, Arizona • Lancaster, California • Los Angeles, California + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Sep 10, 2026, 7:48 AM EDT
Terminated Phase 4 Interventional Results available

Effect of Dupilumab (Anti-IL4Rα) on the Host-Microbe Interface in Atopic Dermatitis

NCT03389893
View directory record Official record
Conditions
Atopic Dermatitis (AD)
Interventions
Dupilumab, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
9
States / cities
La Jolla, California • Los Angeles, California • Stanford, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2021 · Synced Sep 10, 2026, 7:48 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Safety, Tolerability, and Pharmacokinetics of Multiple-Ascending Dose Basimglurant in Healthy Subjects and in Patients With Major Depressive Disorder (MDD)

NCT02433093
View directory record Official record
Conditions
Major Depressive Disorder, Healthy Volunteer
Interventions
Basimglurant, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Garden Grove, California
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Sep 10, 2026, 7:48 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults

NCT04966871
View directory record Official record
Conditions
Malaria
Interventions
PfSPZ Vaccine, PfSPZ Challenge (7G8) for CHMI, Normal Saline
Biological · Other
Lead sponsor
Sanaria Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 17, 2022 · Synced Sep 10, 2026, 7:48 AM EDT
Recruiting Phase 2 Interventional

NSAID Use After Robotic Partial Nephrectomy

NCT05842044
View directory record Official record
Conditions
Kidney Cancer, Renal Cancer, Renal Neoplasm
Interventions
Ketorolac, Acetaminophen, Oxycodone, Hydromorphone, Ibuprofen
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 99 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Sep 10, 2026, 7:48 AM EDT
Terminated Phase 4 Interventional Results available

Steroids in Total Knee Arthroplasty

NCT02219581
View directory record Official record
Conditions
Postoperative Pain, Inflammation, Osteoarthritis
Interventions
Dexamethasone 10 mg, Dexamethasone 20 mg, Standard multimodal pain management regimen, Placebo
Drug
Lead sponsor
Thomas L Bradbury
Other
Eligibility
18 Years to 100 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Tucker, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 3, 2022 · Synced Sep 10, 2026, 7:48 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study of Acetaminophen for Post Surgical Dental Pain

NCT04018612
View directory record Official record
Conditions
Pain, Postoperative, Dental Pain
Interventions
Acetaminophen, Placebo
Drug · Other
Lead sponsor
Nevakar, Inc.
Industry
Eligibility
17 Years to 55 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Sep 10, 2026, 7:48 AM EDT
Terminated Phase 2 Interventional Results available

Study to Assess Safety, Tolerability and Efficacy of SC Administered MBL949 in Obese Participants With or Without T2DM

NCT05199090
View directory record Official record
Conditions
Obesity
Interventions
MBL949, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
4
States / cities
Miami, Florida • Morehead City, North Carolina • Knoxville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Sep 10, 2026, 7:48 AM EDT
Completed Phase 3 Interventional Results available

Phase III Cat-PAD Study

NCT01620762
View directory record Official record
Conditions
Rhinoconjunctivitis
Interventions
Cat-PAD, Placebo
Drug
Lead sponsor
Circassia Limited
Industry
Eligibility
12 Years to 65 Years
Enrollment
1,408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
52
States / cities
Rolling Hills Estates, California • Colorado Springs, Colorado • Denver, Colorado + 49 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Sep 10, 2026, 7:48 AM EDT
Completed Phase 4 Interventional

Methylprednisolone Taper After Total Knee Replacement

NCT05859269
View directory record Official record
Conditions
Knee Arthritis
Interventions
Methylprednisolone, Standard of Care
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 95 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Atlanta, Georgia • Tucker, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Sep 10, 2026, 7:48 AM EDT
Terminated Phase 2 Interventional

AEG35156 in Combination With High-dose Cytarabine and Idarubicin in AML Following Failure of a Single Standard Dose Cytarabine Based Frontline Induction Regimen

NCT01018069
View directory record Official record
Conditions
Leukemia
Interventions
AEG35156
Drug
Lead sponsor
Aegera Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
6
States / cities
Los Angeles, California • Denver, Colorado • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2011 · Synced Sep 10, 2026, 7:48 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Does a Preoperative Bowel Regimen Change Time to First Bowel Movement After Robotic Sacral Colpopexy

NCT04197869
View directory record Official record
Conditions
Constipation, Post-Op Complication
Interventions
Polyethylene Glycol Powder
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 89 Years · Female only
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Bay Shore, New York
Source: ClinicalTrials.gov public record
Updated Dec 26, 2024 · Synced Sep 10, 2026, 7:48 AM EDT
Recruiting No phase listed Observational

Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer

NCT07028489
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Not listed
Lead sponsor
N-Power Medicine
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
9
States / cities
Monterey, California • Torrance, California • Walnut Creek, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 10, 2026, 7:48 AM EDT
Completed Phase 3 Interventional Results available

A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment

NCT00703118
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Telaprevir, Peg-IFN-alfa-2a, Ribavirin, Placebo
Drug
Lead sponsor
Tibotec BVBA
Industry
Eligibility
18 Years to 70 Years
Enrollment
663 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
31
States / cities
Birmingham, Alabama • Coronado, California • La Jolla, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2014 · Synced Sep 10, 2026, 7:48 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Intraoperative Methadone Administration for Improved Pain Control in Spinal Fusion Patients

NCT02989597
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Methadone Hydrochloride, Standard pain regimen, Spinal Fusion Surgery, Dexamethasone, Ketamine, Remifentanil, Sufentanil
Drug · Other · Procedure
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2023 · Synced Sep 10, 2026, 7:48 AM EDT
Completed No phase listed Observational

Valproic Acid-associated Hypoalbuminemia in Medically Fragile Patients

NCT00723762
View directory record Official record
Conditions
Hypoalbuminemia
Interventions
Specimen collection
Procedure
Lead sponsor
Akron Children's Hospital
Other
Eligibility
Not listed
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Mantua, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 9, 2011 · Synced Sep 10, 2026, 7:48 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of Age

NCT00345579
View directory record Official record
Conditions
Haemophilus Influenzae Type b, Neisseria Meningitidis
Interventions
GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined 792014, ActHIB, Pediarix/Infanrix Penta
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 12 Weeks
Enrollment
4,432 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
61
States / cities
Birmingham, Alabama • Benton, Arkansas • Fayetteville, Arkansas + 51 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Sep 10, 2026, 7:48 AM EDT
Not listed Phase 2Phase 3 Interventional

Thalidomide for Patients With Mild to Moderate Alzheimer's Disease

NCT01094340
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Thalidomide
Drug
Lead sponsor
Banner Health
Other
Eligibility
50 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Sun City, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 7, 2012 · Synced Sep 10, 2026, 7:48 AM EDT
Recruiting No phase listed Observational

Evaluate the Effects of Long-term Use of Psychotropic Medications on Eye Movement Patterns With the Gaize Device

NCT07389473
View directory record Official record
Conditions
ADHD, Depression Disorders, Mood Disorders, Anxiety Disorder Generalized, Bipolar Disorder (BPD)
Interventions
Prescription Psychotropic Medications
Drug
Lead sponsor
Gaize
Industry
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Sep 10, 2026, 7:48 AM EDT
Terminated Phase 3 Interventional Results available

S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer

NCT02137837
View directory record Official record
Conditions
Breast Cancer
Interventions
Fulvestrant, Anastrozole, Everolimus, Placebo - Anastrozole, Placebo - Everolimus
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older · Female only
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
223
States / cities
Anchorage, Alaska • Scottsdale, Arizona • Tucson, Arizona + 150 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Sep 10, 2026, 7:48 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study of Sabroxy™ (Oroxylum Indicum Extract) for Improving Cognitive Function in Adults With Mild Memory Concerns

NCT07189754
View directory record Official record
Conditions
Mild Cognitive Impairment (MCI), Cognitive Dysfunction, Cognitive Disorder, Memory Problems
Interventions
Sabroxy™ (Oroxylum indicum extract), Placebo
Dietary Supplement · Other
Lead sponsor
SF Research Institute, Inc.
Network
Eligibility
60 Years to 85 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Sep 10, 2026, 7:48 AM EDT